The latest information regarding the BioCanRx research network and biotherapeutic research.
View this email in your browser
   BioCanRx rolling, open call for funding
   Deadline: Stay tuned! 

   Other funding opportunities currently available:

   Canadian Cancer Society: Knowledge to Action Grants
   Deadline: February 1, 2017

   Prostate Cancer Canada: Movember Discovery Grants
   Deadline: TBC
Cells... in a box
By Heather Blumenthal

It’s like magic – insert a cancer patient’s blood cells in one end and out the other end come T-cells adapted for cell therapy.

But it’s not magic – it’s a very real and very promising way of making sure that the materials exist to better treat patients with cancer using immunotherapy.
It’s a natural progression in the innovation process, says Dr. Jonathan Bramson of McMaster University. First come innovations in technology – in this case, a new way of treating cancer from the inside, using a patient’s own immune cells. These innovations in turn drive innovations in manufacturing.

CellCAN is producing its first Pancanadian Strategic Forum on Cell & Gene Therapy in partnership with the Centre for Commercialization of Cancer Immunotherapy (C3i) and BioCanRx. This forum, which promises to be truly unique and innovative, represents a great opportunity to identify concrete actions—from research to commercialization—that can be taken to help stakeholders in the field become better equipped to develop the therapies of the future.
Bringing together a number of national and international experts such as Catherine Bollard, Chris Mason, Jerome Ritz, Adrian Gee and Isabelle Rivière, this forum will:
  • Highlight the most recent innovations in cell therapy, including cancer immunotherapies.
  • Reveal facilitators and barriers to cell and gene therapy translation in Canada.
  • Identify lessons learned and the promising technologies in manufacturing.
  • Build on effective commercialization strategies for the benefit of all Canadians.
  • Highlight paths to financing and reimbursement.
  • Discuss issues related to cell and gene therapy regulation.
This unique forum will bring together the scientific, academic, clinical, pharmaceutical and biotechnology communities, among others. This multidisciplinarity will encourage strategic collaboration on an unprecedented level between different contributors to the cell and gene therapy sector and will help us build an even stronger ecosystem.
Join us in Montreal on March 9 & 10, 2017.

This is an excellent learning and networking opportunity for HQP in the cancer immunotherapy space to learn about the clinical, social and economic impacts of exciting biotherapeutics for Canadians, our biotechnology sector, and our healthcare system. For this reason, BioCanRx is offering Travel Awards for this event. Please click the following link to apply: BioCanRx Travel Award Pancanadian Strategic Forum on Cell & Gene Therapy.

If you have any questions about the event, please visit or contact the management team at Registration is already open; hurry up, the early-bird registration deadline is December 31, 2016 at 11:59 PM PDT.
You can find information about training, education and career opportunities at the BioCanRx Training website.
BioCanRx releases inaugural Annual Report
BioCanRx | December 7, 2016

We are pleased to share with you BioCanRx's inaugural 2015-16 annual report. The report presents the world-class research currently underway in the network and describes our efforts to bring forward the outcomes of this research to the clinic where patients need it most.  

Click here to read the report
cancer summit, cancer conference
Other upcoming events and opportunities:

Innovative approaches to optimal cancer care in Canada
CPAC | April 7-8, 2017

Science Odyssey - Ten days of discovery and innovation
May 12 to 21, 2017

ARCC Conference 2017
May 25 to 26, 2017 | Toronto, ON
Network members: Feature your research here by sending us a link to your recent publication!
CAR T cell immunotherapy continues to yield complete response in leukemia
Medical Xpress | December 5, 2016

Can CAR-T cancer treatments be fine-tuned to avoid toxic side effects?
FierceBiotech | December 5, 2016

IBM unveils Watson for drug R&D, teams with Pfizer on oncology
FierceBiotech | December 1, 2016

Parker Institute for Cancer Immunotherapy and Cancer Research Institute collborate on cancer neoantigens
Parker ICI | December 1, 2016

Cancer treatments approved by Health Canada marred by major provincial reality disconnect for patients
Save your Skin Foundation | November 22, 2016

Viralytics' anticancer aces checkpoint inhibitor combo trials
FierceBiotech | November 21, 2016
Copyright © BioCanRx, All rights reserved.

Be a part of the BioCanRx community! Please send news and information to:
Danielle Jones, Officer, Communications and Marketing, BioCanRx

Our mailing address is:
501 Smyth Road, Box 611, Ottawa, Ontario K1H 8L6

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

This email was sent to
why did I get this?    unsubscribe from this list    update subscription preferences
BioCanRx · 501 Smyth Road, Box 611 · Ottawa, On K1H 8L6 · Canada

Email Marketing Powered by Mailchimp